Led · Equity · Sep 2025

Harbor Health is a primary and specialty care clinic group and health insurance company that pairs care delivery with longitudinal coverage models. The company connects each member to a dedicated health team and customized care pathways, integrating primary care with specialty services. Harbor Health serves more than 50,000 people in Central Texas, reports a net promoter score of 90, and has grown from three clinics in 2022 to 11 clinics, plus two mobile clinics and an infusion center. It plans to expand its clinical footprint across Texas and add specialty service lines including rheumatology, dermatology, cardiology, endocrinology, and mental health. In November 2025 Harbor Health will offer fully insured individual and family plans on healthcare.gov while continuing to provide quotes for large employer plans in Central Texas. The company says its integrated care-and-coverage model can deliver 10–20% savings while improving outcomes. Harbor Health is an Austin, TX-based primary and specialty clinic group that delivers primary care and expanded specialty services for employers, providers and individual consumers. The team connects consumers to a dedicated health team and customized care pathways, emphasizing a personalized, relationship-driven approach. The company says this model helps consumers get healthier faster and reduces the emotional and financial burdens of the current healthcare system. Harbor Health plans to use new funding to accelerate growth in primary care services, broaden its specialty care offerings, and develop plan designs that support care journeys co-created by consumers and their clinicians. The company was founded by Dr. Clay Johnston, Eric Scott (from 8VC) and Tony Miller.

Participated · Series C · Jan 2025

Be Bio pioneers Engineered B Cell Medicines (BCMs), a platform that programs primary human B cells to produce therapeutic proteins continuously and durably. Its lead programs, BE-101 (Factor IX for hemophilia B) and BE-102 (alkaline phosphatase for hypophosphatasia), are built on this BCM platform and designed to be titratable and re-dosable without preconditioning. BE-101 has an FDA-cleared IND (May 2024), Fast Track designation (September 2024), and is being evaluated in the Phase 1/2 BeCoMe-9 trial to generate clinical proof-of-concept. BE-102 has been selected as a development candidate and is being advanced toward the clinic. The company says proceeds from the Series C will advance BE-101 through proof-of-concept and move BE-102 into clinical development. Be Bio was founded in October 2020 and is based in Cambridge, Mass. Be Biopharma develops engineered B Cell Medicines (BCMs) to improve outcomes for patients with Hemophilia B, other genetic diseases, cancer, and other serious conditions. Its lead program, BE-101, is engineered to insert the human Factor IX (FIX) gene into primary human B cells to enable continuous expression of active FIX. BE-101 aims to deliver sustained therapeutic FIX activity with a single infusion, with the flexibility to be titrated or re-dosed and without the need for preconditioning. The US FDA cleared the BE-101 IND in May 2024 and granted Fast Track designation in September 2024. The company has initiated the Phase 1/2 BeCoMe-9 trial and plans to use the new funding to achieve clinical proof of concept for BE-101 and to advance BE-102. Be Biopharma is led by CEO Joanne Smith-Farrell and is based in Cambridge, MA. Be Biopharma develops Engineered B Cell Medicines (BeCM), operating autologous and allogeneic B‑cell therapy platforms. The company is advancing a broad pipeline initially focused on rare disease and cancer. As it develops its platform, Be Biopharma plans to expand into infectious disease, neurological conditions and autoimmune disease. It closed a $130M financing to support platform advancement and to progress pipeline candidates toward the clinic, bringing total investment to over $180M. Founded in October 2020 and based in Cambridge, MA, the company was launched by Longwood Fund and B‑cell engineering pioneers David Rawlings and Richard James, and is led by CEO Joanne Smith‑Farrell. Be Biopharma develops engineered B cells as a new category of medicines, using the human body's native protein factories to produce therapeutic proteins. The company aims to precisely engineer B cells to exploit their high protein production, selective tissue targeting, and potentially long programmable lifetimes. Be Bio intends its medicines to be durable, re-dosable, and administered without toxic conditioning, opening avenues to treat cancer, autoimmune diseases, monogenic disorders, and enhance responses to infectious pathogens. The platform builds on pioneering work by David Rawlings and Richard James at Seattle Children’s Research Institute. Leadership and scientific founders include Longwood Fund, David Rawlings, Richard James, David Steinberg (CEO and co-founder), Aleks Radovic-Moreno, and Lea Hachigian. The company is based in Cambridge, Mass.

Participated · Series C · Nov 2024

TransMedics, founded in 1998, develops the Organ Care System, an investigational organ transport device designed to maintain organs in a warm, functioning state outside the body. The system aims to optimize organ health during transport, increase the number of usable donor organs, and enable living organ transplant. TransMedics recently initiated the European PROTECT trial to evaluate the Organ Care System for heart transplants. The company plans to extend the platform to other organs, including lung, liver and kidneys, and to commercialize the device. It is privately held and raised $29.75 million in Series C financing to accelerate growth, continue the PROTECT trial, and initiate new studies in Europe and the U.S. Company leadership indicated a target for European market approval early in 2007. TransMedics Group is a medical technology company built to address the need for more and better donor organs by developing portable extracorporeal warm perfusion and organ assessment technologies. The company’s Organ Care System (OCS) program focuses on preserving organ quality and assessing viability prior to transplant to potentially increase donor-organ utilization for end-stage heart, lung, and liver failure. TransMedics plans to use incremental growth capital to accelerate its commercial momentum, grow transplant volume, and improve clinical outcomes. The company said the new financing is non-dilutive and will provide financial flexibility as it scales the business. TransMedics was founded in 1998 and is headquartered in Andover, Massachusetts. The company intends to use the capital to retire existing debt and support continued market expansion. TransMedics has developed the Organ Care System (OCS), a portable technology and multi-organ platform designed to maintain donor organs in a near-physiologic state outside the body to improve transplant outcomes and expand the pool of transplantable organs. The company’s OCS Heart and OCS Lung systems are CE Marked and are used by transplant centers in Europe, Australia and Canada. The OCS Heart, Lung and Liver systems are in clinical trials in the United States. TransMedics is led by Dr. Waleed Hassanein, President and CEO. The company recently closed a $51.2M growth equity financing. TransMedics develops a portable warm blood perfusion system—referred to in coverage as an Organ Care System—that keeps donor organs functioning outside the body instead of on ice. The device is positioned as a “living organ transplant” solution intended to improve organ condition prior to transplant surgery. Reported benefits include the ability to resuscitate hearts from donors after circulatory death and to identify pathologically abnormal hearts that might be missed with cold static storage. A study and accompanying editorial in The Lancet found short-term outcomes comparable to cold storage but noted the system could reveal abnormalities and that more study is needed. The privately held Boston company was launched in 1998 and has raised well over $100 million to date, leaving it well-capitalized. CEO Waleed Hassanein has publicly criticized cooler-based transport and promoted the system as a better method for organ preservation and transport. TransMedics is an Andover, Massachusetts–based medical technology company focused on extending the life-saving benefits of organ transplantation. Led by President and CEO Dr. Waleed Hassanein, the company develops the Organ Care System (OCS™) Heart and Lung devices. The OCS devices are portable preservation technologies that maintain donor organs in a near-physiologic and functioning condition from donor to transplant recipient. TransMedics closed a $36M financing to support its programs. The company intends to use the funding to complete its heart and lung FDA pivotal trials and expand global commercial activities. In conjunction with the financing, representatives from the lead investor joined TransMedics’ Board of Directors.

Participated · Series D · Sep 2024

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.

Participated · Series A · May 2024

Progentos discovers and develops first-in-class small‑molecule drugs that induce endogenous oligodendrocyte progenitor cells to remyelinate axons damaged by demyelinating diseases such as multiple sclerosis. Its proprietary molecules reportedly outperform previous approaches at differentiating OPCs into new oligodendrocytes and regenerate myelin in in vivo models. The company announced its launch concurrent with this financing and plans to advance its MS program into human proof-of-concept studies. Progentos also intends to expand its pipeline into additional degenerative diseases. The company will operate from Watertown, Massachusetts and Naarden, The Netherlands. Management emphasizes the unmet need for therapies that restore function by regenerating myelin.